Lessons from failure--preparing for future HIV-1 vaccine efficacy trials

Editorial

Barney S Graham et al. J Infect Dis. 2005.

. 2005 Mar 1;191(5):647-9.

doi: 10.1086/428406. Epub 2005 Jan 27.

No abstract available

Comment on

Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection.
Flynn NM, Forthal DN, Harro CD, Judson FN, Mayer KH, Para MF; rgp120 HIV Vaccine Study Group. Flynn NM, et al. J Infect Dis. 2005 Mar 1;191(5):654-65. doi: 10.1086/428404. Epub 2005 Jan 27. J Infect Dis. 2005. PMID: 15688278 Clinical Trial.
Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial.
Gilbert PB, Peterson ML, Follmann D, Hudgens MG, Francis DP, Gurwith M, Heyward WL, Jobes DV, Popovic V, Self SG, Sinangil F, Burke D, Berman PW. Gilbert PB, et al. J Infect Dis. 2005 Mar 1;191(5):666-77. doi: 10.1086/428405. Epub 2005 Jan 27. J Infect Dis. 2005. PMID: 15688279 Clinical Trial.